A Review of the Management of Chronic Myeloid Leukemia with Dasatinib
Clinical Medicine. Therapeutics · 2009
DOI: 10.4137/cmt.s1167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Medicine. Therapeutics, 2009. Verfasst von Joanna Gora-Tybor und 1 weiteren Autor:innen. Die Arbeit nennt 65 Literaturangaben.
Abstract (Originalsprache)
Dasatinib is a multitargeted tyrosine kinase inhibitor (TKI), recommended for chronic myeloid leukemia (CML) in chronic, accelerated and blastic phases that are resistant or intolerant to imatinib. The recognition of BCR-ABL gene and corresponding protein with deregulated tyrosine kinase (TK) activity as crucial for malignant transformation in CML, led to synthesis of the small-molecule drugs designed to interfere with Bcr-Abl TK activation. The first TKI introduced into clinical practice in 1998, was imatinib mesylate, which became the first choice drug in chronic phase CML. However, approximately 20%-25% of patients initially successfully treated with imatinib, develop resistance to this drug, mainly because of selection of clones expressing mutant forms of BCR-ABL with impairing imatinib binding. Dasatinib is 325-fold more potent than imatinib against cell expressing wild-type BCR-ABL and showing activity against most imatinib-resistant Bcr-Abl mutants. Several clinical trials demonstrated that dasatinib is effective and generally well tolerated in imatinib resistant or intolerant CML and represents a promising therapeutic option for these patients.
Zitieren
APA
Gora-Tybor, J., & Robak, T. (2009). A Review of the Management of Chronic Myeloid Leukemia with Dasatinib. Clinical Medicine. Therapeutics. https://doi.org/10.4137/cmt.s1167
Vancouver
Gora-Tybor J, Robak T. A Review of the Management of Chronic Myeloid Leukemia with Dasatinib. Clinical Medicine. Therapeutics. 2009. doi:10.4137/cmt.s1167
BibTeX
@article{GoraTybor2009,
author = {Gora-Tybor, Joanna and Robak, Tadeusz},
title = {A Review of the Management of Chronic Myeloid Leukemia with Dasatinib},
journal = {Clinical Medicine. Therapeutics},
year = {2009},
doi = {10.4137/cmt.s1167}
}
EUVIMED